Boehringer Ingelheim announced a further expansion and upgrade of its plant in Koropi, Greece.
With an investment of EUR 120 million, the company will increase the manufacturing capacity of new and existing medications, some of them in the late-stage development of the company’s strong innovation pipeline. The main disease areas include cardio-renal-metabolic (CRM) diseases,…